Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy KLTO?
Source: PRnewswire
Award Recognition: Klotho Neurosciences, Inc. has won the Fifth Annual BioTech Breakthrough Award for "Cell Therapy Innovation of the Year" for its groundbreaking work in gene and cell therapies targeting neurodegenerative diseases.
Innovative Therapies: The company focuses on using a patented form of the human Klotho gene (s-KL) to develop therapies aimed at slowing or reversing diseases like ALS, Alzheimer's, and Parkinson's, addressing the root causes of neuronal aging.
Commitment to Patients: CEO Dr. Joseph Sinkule emphasized the importance of developing therapies that improve health span and reduce the burden of age-related diseases, especially as the global population ages.
BioTech Breakthrough Awards: The awards program recognizes innovative companies and technologies in the life sciences and biotechnology sectors, celebrating excellence in various fields including biopharma and therapeutics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KLTO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KLTO
About KLTO
Klotho Neurosciences, Inc. operates with two divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The Skaergaard Project is located in Southeast Greenland, which is an undeveloped palladium, gold, and platinum deposit. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It is engaged in developing and providing new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. It is also focusing on developing therapeutic agents for the treatments for Alzheimer's and Parkinson's disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Klotho Rebrands to Greenland Mines Ltd Amid Strategic Shift
- Corporate Rebranding: Klotho Neurosciences, Inc. officially rebrands to Greenland Mines Ltd on March 12, 2026, changing its stock ticker to "GRML", which will automatically update in existing shareholders' brokerage accounts, aiming to enhance market recognition and brand image.
- Investor Webcast Announcement: The company will hold an investor webcast on March 12, 2026, at 4:15 PM ET to discuss the strategic rationale behind its recent acquisition and the potential benefits for shareholders, thereby boosting investor confidence.
- Focus on Resource Development: Greenland Mines Ltd is primarily focused on the Skaergaard Project in Greenland, which is one of the largest undeveloped palladium and gold deposits globally, boasting 25.4 million ounces of PdEq and 23.5 million ounces of AuEq, with an estimated gross resource value of approximately $68 billion, indicating significant commercial potential.
- Experienced Management Team: The company is led by a seasoned team of professionals from mining, geology, biotech, and capital markets, aiming to leverage their expertise to drive resource development and business growth, thereby enhancing the company's competitiveness in the mining sector.
See More
Klotho Changes Name to Greenland Mines Ltd, Focuses on Critical Minerals
- Corporate Name Change: Klotho Neurosciences, Inc. officially rebranded to Greenland Mines Ltd on March 12, 2026, with its stock ticker changing to GRML, reflecting the company's commitment to a strategic transformation without requiring action from existing shareholders.
- Investor Webcast Announcement: The company will hold an investor webcast on March 12, 2026, at 4:15 PM ET to discuss the strategic rationale behind its recent acquisition and the benefits for shareholders, aiming to enhance investor confidence and market visibility.
- Mineral Resource Development: Greenland Mines Ltd acquired an 80% interest in the Skaergaard Project through its acquisition of Greenland Mines Corp., which is one of the largest undeveloped deposits of palladium, gold, and platinum globally, with a 2022 mineral resource estimate of 25.4 million ounces PdEq and 23.5 million ounces AuEq, representing a gross resource value of approximately $68 billion, showcasing the company's significant potential in the mining sector.
- Diversified Business Strategy: The company not only focuses on natural resource development but also engages in cell and gene therapy, particularly with its KLTO-202 for ALS, reflecting a diversified strategy in both biotechnology and mining sectors aimed at driving long-term growth through technological innovation.
See More
Klotho Acquires Greenland Mines, Opening New Chapter
- Major Acquisition: Klotho Neurosciences acquires Greenland Mines Corp. for convertible preferred stock, securing an 80% stake and an option for the remaining 20%, marking direct ownership in one of the world's largest undeveloped palladium, gold, and platinum deposits, which is expected to significantly enhance the company's position in critical mineral supply security.
- Resource Value: The Skaergaard Project boasts a total resource value of approximately $68 billion, with palladium, gold, and platinum valued at $30.8 billion, $34.8 billion, and $3 billion respectively, highlighting the project's significance in global mining and offering substantial potential returns for shareholders.
- Strategic Restructuring: Post-acquisition, Klotho will reorganize into two strategic operating divisions: Natural Resources and Cell and Gene Therapy, aiming to combine world-class mineral assets with its biotech platform to provide diversified investment opportunities and enhance competitiveness in the critical minerals sector.
- Market Opportunity: Amidst tightening global palladium supply, the development of the Skaergaard Project will provide a secure alternative source for the U.S. and Europe, reducing reliance on Russia and South Africa, aligning with current strategic needs for critical mineral resource security.
See More
Klotho Neurosciences Secures Patent Claims for s-KL Protein
- Patent Progress: Klotho Neurosciences has received approval for 18 claims in its patent application in Australia, covering the use of human secreted Klotho protein (s-KL), marking a significant advancement in the treatment of neuromuscular diseases.
- Therapeutic Potential: The patents include the use of a muscle-cell specific promoter linked to the s-KL gene sequence for treating motor impairment, which is expected to enhance the company's competitive edge in the neurodegenerative disease market.
- Technical Collaboration: Klotho's licensing agreement with Universitat Autonoma de Barcelona further solidifies its innovative capabilities in gene and cell therapy, propelling the clinical application development of s-KL protein.
- Market Outlook: As Klotho levels naturally decline with age, the acquisition of this patent opens new commercial opportunities for the company, particularly in treating neuromuscular diseases such as ALS.
See More
Klotho CEO Dr. Joseph Sinkule to Present at Biotech Showcase on January 13, 2026
- Showcase Participation: Klotho Neurosciences, Inc. CEO Dr. Joseph Sinkule will present at the Biotech Showcase on January 13, 2026, at 11:30 AM PT in San Francisco, highlighting the company's innovations in biogenetics.
- Investor Meetings: The company will hold one-on-one meetings with investors and potential partners during the event, aiming to strengthen connections with key stakeholders in the industry and drive future collaboration opportunities.
- Technological Focus: Klotho specializes in developing cell and gene therapies based on the human Klotho gene, aiming to improve treatments for neurodegenerative diseases, showcasing its technological potential in the biopharmaceutical sector.
- Market Outlook: This event provides Klotho with an opportunity to showcase its innovative therapies, potentially attracting investor interest and laying the groundwork for the company's future commercial operations.
See More
Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding
- Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
- Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
- Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
- Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.
See More
Klotho Rebrands to Greenland Mines Ltd Amid Strategic Shift
- Corporate Rebranding: Klotho Neurosciences, Inc. officially rebrands to Greenland Mines Ltd on March 12, 2026, changing its stock ticker to "GRML", which will automatically update in existing shareholders' brokerage accounts, aiming to enhance market recognition and brand image.
- Investor Webcast Announcement: The company will hold an investor webcast on March 12, 2026, at 4:15 PM ET to discuss the strategic rationale behind its recent acquisition and the potential benefits for shareholders, thereby boosting investor confidence.
- Focus on Resource Development: Greenland Mines Ltd is primarily focused on the Skaergaard Project in Greenland, which is one of the largest undeveloped palladium and gold deposits globally, boasting 25.4 million ounces of PdEq and 23.5 million ounces of AuEq, with an estimated gross resource value of approximately $68 billion, indicating significant commercial potential.
- Experienced Management Team: The company is led by a seasoned team of professionals from mining, geology, biotech, and capital markets, aiming to leverage their expertise to drive resource development and business growth, thereby enhancing the company's competitiveness in the mining sector.
See More
Klotho Changes Name to Greenland Mines Ltd, Focuses on Critical Minerals
- Corporate Name Change: Klotho Neurosciences, Inc. officially rebranded to Greenland Mines Ltd on March 12, 2026, with its stock ticker changing to GRML, reflecting the company's commitment to a strategic transformation without requiring action from existing shareholders.
- Investor Webcast Announcement: The company will hold an investor webcast on March 12, 2026, at 4:15 PM ET to discuss the strategic rationale behind its recent acquisition and the benefits for shareholders, aiming to enhance investor confidence and market visibility.
- Mineral Resource Development: Greenland Mines Ltd acquired an 80% interest in the Skaergaard Project through its acquisition of Greenland Mines Corp., which is one of the largest undeveloped deposits of palladium, gold, and platinum globally, with a 2022 mineral resource estimate of 25.4 million ounces PdEq and 23.5 million ounces AuEq, representing a gross resource value of approximately $68 billion, showcasing the company's significant potential in the mining sector.
- Diversified Business Strategy: The company not only focuses on natural resource development but also engages in cell and gene therapy, particularly with its KLTO-202 for ALS, reflecting a diversified strategy in both biotechnology and mining sectors aimed at driving long-term growth through technological innovation.
See More
Klotho Acquires Greenland Mines, Opening New Chapter
- Major Acquisition: Klotho Neurosciences acquires Greenland Mines Corp. for convertible preferred stock, securing an 80% stake and an option for the remaining 20%, marking direct ownership in one of the world's largest undeveloped palladium, gold, and platinum deposits, which is expected to significantly enhance the company's position in critical mineral supply security.
- Resource Value: The Skaergaard Project boasts a total resource value of approximately $68 billion, with palladium, gold, and platinum valued at $30.8 billion, $34.8 billion, and $3 billion respectively, highlighting the project's significance in global mining and offering substantial potential returns for shareholders.
- Strategic Restructuring: Post-acquisition, Klotho will reorganize into two strategic operating divisions: Natural Resources and Cell and Gene Therapy, aiming to combine world-class mineral assets with its biotech platform to provide diversified investment opportunities and enhance competitiveness in the critical minerals sector.
- Market Opportunity: Amidst tightening global palladium supply, the development of the Skaergaard Project will provide a secure alternative source for the U.S. and Europe, reducing reliance on Russia and South Africa, aligning with current strategic needs for critical mineral resource security.
See More
Klotho Neurosciences Secures Patent Claims for s-KL Protein
- Patent Progress: Klotho Neurosciences has received approval for 18 claims in its patent application in Australia, covering the use of human secreted Klotho protein (s-KL), marking a significant advancement in the treatment of neuromuscular diseases.
- Therapeutic Potential: The patents include the use of a muscle-cell specific promoter linked to the s-KL gene sequence for treating motor impairment, which is expected to enhance the company's competitive edge in the neurodegenerative disease market.
- Technical Collaboration: Klotho's licensing agreement with Universitat Autonoma de Barcelona further solidifies its innovative capabilities in gene and cell therapy, propelling the clinical application development of s-KL protein.
- Market Outlook: As Klotho levels naturally decline with age, the acquisition of this patent opens new commercial opportunities for the company, particularly in treating neuromuscular diseases such as ALS.
See More
Klotho CEO Dr. Joseph Sinkule to Present at Biotech Showcase on January 13, 2026
- Showcase Participation: Klotho Neurosciences, Inc. CEO Dr. Joseph Sinkule will present at the Biotech Showcase on January 13, 2026, at 11:30 AM PT in San Francisco, highlighting the company's innovations in biogenetics.
- Investor Meetings: The company will hold one-on-one meetings with investors and potential partners during the event, aiming to strengthen connections with key stakeholders in the industry and drive future collaboration opportunities.
- Technological Focus: Klotho specializes in developing cell and gene therapies based on the human Klotho gene, aiming to improve treatments for neurodegenerative diseases, showcasing its technological potential in the biopharmaceutical sector.
- Market Outlook: This event provides Klotho with an opportunity to showcase its innovative therapies, potentially attracting investor interest and laying the groundwork for the company's future commercial operations.
See More
Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding
- Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
- Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
- Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
- Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.
See More
